177 related articles for article (PubMed ID: 17318652)
1. A HLA-DQ5 restricted Melan-A/MART-1 epitope presented by melanoma tumor cells to CD4+ T lymphocytes.
Larrieu P; Ouisse LH; Guilloux Y; Jotereau F; Fonteneau JF
Cancer Immunol Immunother; 2007 Oct; 56(10):1565-75. PubMed ID: 17318652
[TBL] [Abstract][Full Text] [Related]
2. Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers.
Bioley G; Jandus C; Tuyaerts S; Rimoldi D; Kwok WW; Speiser DE; Tiercy JM; Thielemans K; Cerottini JC; Romero P
J Immunol; 2006 Nov; 177(10):6769-79. PubMed ID: 17082590
[TBL] [Abstract][Full Text] [Related]
3. A HLA-Cw*0701 restricted Melan-A/MART1 epitope presented by melanoma tumor cells to CD8+ tumor infiltrating lymphocytes.
Larrieu P; Renaud V; Godet Y; Jotereau F; Fonteneau JF
Cancer Immunol Immunother; 2008 May; 57(5):745-52. PubMed ID: 18097665
[TBL] [Abstract][Full Text] [Related]
4. Identification of an HLA-DPB1*0501 restricted Melan-A/MART-1 epitope recognized by CD4+ T lymphocytes: prevalence for immunotherapy in Asian populations.
Meng Z; Wang Y; Zhang G; Ke Y; Yan Y; Wu L; Huang Q; Zeng G; Wang Y; Ying H; Jiao S
J Immunother; 2011 Sep; 34(7):525-34. PubMed ID: 21760531
[TBL] [Abstract][Full Text] [Related]
5. Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells.
Zarour HM; Kirkwood JM; Kierstead LS; Herr W; Brusic V; Slingluff CL; Sidney J; Sette A; Storkus WJ
Proc Natl Acad Sci U S A; 2000 Jan; 97(1):400-5. PubMed ID: 10618430
[TBL] [Abstract][Full Text] [Related]
6. Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy.
Bettinotti MP; Kim CJ; Lee KH; Roden M; Cormier JN; Panelli M; Parker KK; Marincola FM
J Immunol; 1998 Jul; 161(2):877-89. PubMed ID: 9670966
[TBL] [Abstract][Full Text] [Related]
7. Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1.
Schneider J; Brichard V; Boon T; Meyer zum Büschenfelde KH; Wölfel T
Int J Cancer; 1998 Jan; 75(3):451-8. PubMed ID: 9455808
[TBL] [Abstract][Full Text] [Related]
8. Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes.
Benlalam H; Linard B; Guilloux Y; Moreau-Aubry A; Derré L; Diez E; Dreno B; Jotereau F; Labarrière N
J Immunol; 2003 Dec; 171(11):6283-9. PubMed ID: 14634146
[TBL] [Abstract][Full Text] [Related]
9. Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy.
Schultz ES; Schuler-Thurner B; Stroobant V; Jenne L; Berger TG; Thielemanns K; van der Bruggen P; Schuler G
J Immunol; 2004 Jan; 172(2):1304-10. PubMed ID: 14707109
[TBL] [Abstract][Full Text] [Related]
10. Identification of two Melan-A CD4+ T cell epitopes presented by frequently expressed MHC class II alleles.
Godefroy E; Scotto L; Souleimanian NE; Ritter G; Old LJ; Jotereau F; Valmori D; Ayyoub M
Clin Immunol; 2006 Oct; 121(1):54-62. PubMed ID: 16814609
[TBL] [Abstract][Full Text] [Related]
11. Identification of a public CDR3 motif and a biased utilization of T-cell receptor V beta and J beta chains in HLA-A2/Melan-A-specific T-cell clonotypes of melanoma patients.
Serana F; Sottini A; Caimi L; Palermo B; Natali PG; Nisticò P; Imberti L
J Transl Med; 2009 Mar; 7():21. PubMed ID: 19317896
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic T lymphocytes define multiple peptide isoforms derived from the melanoma-associated antigen MART-1/Melan-A.
Jäger E; Höhn H; Karbach J; Momburg F; Castelli C; Knuth A; Seliger B; Maeurer MJ
Int J Cancer; 1999 Jun; 81(6):979-84. PubMed ID: 10362148
[TBL] [Abstract][Full Text] [Related]
13. Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues.
Carrabba MG; Castelli C; Maeurer MJ; Squarcina P; Cova A; Pilla L; Renkvist N; Parmiani G; Rivoltini L
Cancer Res; 2003 Apr; 63(7):1560-7. PubMed ID: 12670905
[TBL] [Abstract][Full Text] [Related]
14. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues.
Valmori D; Fonteneau JF; Lizana CM; Gervois N; Liénard D; Rimoldi D; Jongeneel V; Jotereau F; Cerottini JC; Romero P
J Immunol; 1998 Feb; 160(4):1750-8. PubMed ID: 9469433
[TBL] [Abstract][Full Text] [Related]
15. Use of an in vitro immunoselected tumor line to identify shared melanoma antigens recognized by HLA-A*0201-restricted T cells.
Harada M; Li YF; El-Gamil M; Rosenberg SA; Robbins PF
Cancer Res; 2001 Feb; 61(3):1089-94. PubMed ID: 11221837
[TBL] [Abstract][Full Text] [Related]
16. Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma.
Romero P; Valmori D; Pittet MJ; Zippelius A; Rimoldi D; Lévy F; Dutoit V; Ayyoub M; Rubio-Godoy V; Michielin O; Guillaume P; Batard P; Luescher IF; Lejeune F; Liénard D; Rufer N; Dietrich PY; Speiser DE; Cerottini JC
Immunol Rev; 2002 Oct; 188():81-96. PubMed ID: 12445283
[TBL] [Abstract][Full Text] [Related]
17. Identification of helper T-cell epitopes that encompass or lie proximal to cytotoxic T-cell epitopes in the gp100 melanoma tumor antigen.
Kobayashi H; Lu J; Celis E
Cancer Res; 2001 Oct; 61(20):7577-84. PubMed ID: 11606397
[TBL] [Abstract][Full Text] [Related]
18. Screening of human tumor antigens for CD4 T cell epitopes by combination of HLA-transgenic mice, recombinant adenovirus and antigen peptide libraries.
Osen W; Soltek S; Song M; Leuchs B; Steitz J; Tüting T; Eichmüller SB; Nguyen XD; Schadendorf D; Paschen A
PLoS One; 2010 Nov; 5(11):e14137. PubMed ID: 21152437
[TBL] [Abstract][Full Text] [Related]
19. A long peptide from MELOE-1 contains multiple HLA class II T cell epitopes in addition to the HLA-A*0201 epitope: an attractive candidate for melanoma vaccination.
Rogel A; Vignard V; Bobinet M; Labarriere N; Lang F
Cancer Immunol Immunother; 2011 Mar; 60(3):327-37. PubMed ID: 21080167
[TBL] [Abstract][Full Text] [Related]
20. Establishment of gp100 and MART-1/Melan-A-specific cytotoxic T lymphocyte clones using in vitro immunization against preselected highly immunogenic melanoma cell clones.
Kirkin AF; thor Straten P; Hansen MR; Barfoed A; Dzhandzhugazyan KN; Zeuthen J
Cancer Immunol Immunother; 1999 Aug; 48(5):239-46. PubMed ID: 10478640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]